The Hard Sell
Crime and Punishment at an Opioid Startup
Seiten
2023
Picador (Verlag)
978-1-0350-0970-1 (ISBN)
Picador (Verlag)
978-1-0350-0970-1 (ISBN)
A medical crime story, in the vein of Empire of Pain and Bad Blood, concerned with fentanyl and drawing back the curtains in exposing the on the ground tactics employed in pharmaceutical sales.
Soon to be the major motion picture Pain Hustlers starring Emily Blunt and Chris Evans streaming on Netflix
‘A pacy crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times
In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.
Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids.
With colourful characters and true crime suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .
Soon to be the major motion picture Pain Hustlers starring Emily Blunt and Chris Evans streaming on Netflix
‘A pacy crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times
In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.
Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids.
With colourful characters and true crime suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .
Evan Hughes was a finalist for the National Magazine Award in Reporting in 2015. He has written for The New York Times Magazine, GQ, New York, Wired, and The New York Review of Books. He is the author of Literary Brooklyn and The Hard Sell.
Erscheinungsdatum | 09.01.2023 |
---|---|
Verlagsort | London |
Sprache | englisch |
Maße | 153 x 233 mm |
Gewicht | 358 g |
Themenwelt | Literatur ► Biografien / Erfahrungsberichte |
Medizin / Pharmazie ► Pharmazie | |
Recht / Steuern ► Strafrecht ► Kriminologie | |
Technik | |
ISBN-10 | 1-0350-0970-6 / 1035009706 |
ISBN-13 | 978-1-0350-0970-1 / 9781035009701 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Wie ich als Kopf einer der meistgesuchten Verbrecherbanden mit …
Buch | Hardcover (2023)
riva (Verlag)
20,00 €